MedKoo Cat#: 529406 | Name: Roluperidone
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Roluperidone, also known as MIN-101, CYR-101, and MT-210, is a 5-HT2A and sigma 2 receptor antagonist potentially for the treatment of schizophrenia.

Chemical Structure

Roluperidone
Roluperidone
CAS#359625-79-9

Theoretical Analysis

MedKoo Cat#: 529406

Name: Roluperidone

CAS#: 359625-79-9

Chemical Formula: C22H23FN2O2

Exact Mass: 366.1744

Molecular Weight: 366.43

Elemental Analysis: C, 72.11; H, 6.33; F, 5.18; N, 7.64; O, 8.73

Price and Availability

Size Price Availability Quantity
10mg USD 115.00 Ready to ship
25mg USD 245.00 Ready to ship
50mg USD 400.00 Ready to ship
100mg USD 700.00 Ready to ship
200mg USD 1,250.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MIN-101; MIN 101; MIN101; CYR-101; CYR 101; CYR101; MT-210; MT 210; MT210; Roluperidone
IUPAC/Chemical Name
2-((1-(2-(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one
InChi Key
RNRYULFRLCBRQS-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H23FN2O2/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27/h1-8,16H,9-15H2
SMILES Code
O=C1N(CC2CCN(CC(C3=CC=C(F)C=C3)=O)CC2)CC4=C1C=CC=C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
DMSO 33.3 90.96
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 366.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Davidson M, Saoud J, Staner C, Noel N, Werner S, Luthringer E, Walling D, Weiser M, Harvey PD, Strauss GP, Luthringer R. Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia. Schizophr Bull. 2022 May 7;48(3):609-619. doi: 10.1093/schbul/sbac013. PMID: 35211743; PMCID: PMC9077422. 2: Rabinowitz J, Staner C, Saoud J, Weiser M, Kuchibhatla R, Davidson M, Harvey PD, Luthringer R. Long-term effects of Roluperidone on negative symptoms of schizophrenia. Schizophr Res. 2023 May;255:9-13. doi: 10.1016/j.schres.2023.03.028. Epub 2023 Mar 16. PMID: 36933291. 3: Harvey PD, Saoud JB, Luthringer R, Moroz S, Blazhevych Y, Stefanescu C, Davidson M. Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression. Schizophr Res. 2020 Jan;215:352-356. doi: 10.1016/j.schres.2019.08.029. Epub 2019 Sep 2. PMID: 31488314. 4: James SH, Ahmed AO, Harvey PD, Saoud JB, Davidson M, Kuchibhatla R, Luthringer R, Strauss GP. Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition. Eur Neuropsychopharmacol. 2024 Oct;87:18-23. doi: 10.1016/j.euroneuro.2024.07.005. Epub 2024 Jul 17. PMID: 39024856. 5: Strauss GP, Zamani Esfahlani F, Sayama H, Kirkpatrick B, Opler MG, Saoud JB, Davidson M, Luthringer R. Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial. Schizophr Bull. 2020 Jul 8;46(4):964-970. doi: 10.1093/schbul/sbz141. PMID: 31989151; PMCID: PMC7342174. 6: Rabinowitz J, Badescu S, Palamarchuk P, Filyk V, Voloshchuk A, Rud V, Melnyk E, Skrypnikov A, Davidson M, Saoud J, Luthringer R. Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial. Schizophr Res. 2019 Sep;211:103-104. doi: 10.1016/j.schres.2019.07.029. Epub 2019 Jul 30. PMID: 31375316.